A Phase I, Open-Label, Dose-Finding Study of GSK2636771 Administered in Combination with Enzalutamide (Xtandi) in Male Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

SUMMARY

N/A

COH Protocol Number : 14256

ClinicalTrials.gov Number : NCT02215096

Principal Investigator : Twardowski, Przemyslaw M.D.

Sponsor : GlaxoSmithKline

BRIEF ELIGIBILITY CRITERIA :

Eligible Ages : >=18

Gender : Male

Minimum Performance Status : ECOG/SWOG:1

Treatment Intent : Non-Adjuvant treatment

Prior Chemotherapy :

Brain Metastases :

Measurable Disease :